Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, SynapDx Join Forces on ASD

NEW YORK (GenomeWeb News) – SynapDx today announced a deal with Illumina aimed at the detection of autism spectrum disorders.

The deal will link SynapDx's autism technologies with Illumina's sequencing platforms to develop tools for the early detection of ASDs, SynapDx said, adding that the companies will also broadly evaluate other opportunities in neurodevelopment.

Further terms were not disclosed.

Lexington, Mass.-based SynapDx is developing a blood-based ASD test for the early detection of children with autism. Two weeks ago, Laboratory Corporation of America injected $2 million into SynapDx to accelerate the development of the test, and in December, SynapDx completed a Series A1 financing round that brought in $6 million to support a clinical study for the test.

"Our relationship with SynapDx highlights our commitment to collaborating with cutting-edge companies doing truly innovative work that will improve patient care," Matt Posard, senior vice president and general manager of Illumina's Translational and Consumer Genomics business, said in a statement. "SynapDx's commitment to the early detection of autism makes our work together truly meaningful, and we are pleased to join forces in this important effort."